Table 1

Gene expression signature for GC-sensitivity in CEM cells. (Signaling Network Genes)


Sensitive
 Sensitive
 Sensitive
 Sensitive
 Resensitized
 Resistant
Name
 Description
 C7–14 Dx
 C7–14 Z
 C1–6 Dx
 C1–15 Z
 C1–15 Dx+F
 C1–15 Dx
AK2
 adenylate kinase 2
 -1.4
 -1.7
 -1.6
 -1.6
 -1.4
 *
ARHGEF7
 Rho guanine nucleotide exchange factor (GEF) 7
 1.3
 1.4
 1.3
 1.3
 1.8
 1.2
BCL2L11
 BCL2-like 11 (apoptosis facilitator)
 3.1
 14.5
 5.9
 1.3
 1.8
 *
CALR
 calreticulin
 -1.9
 -1.7
 -1.6
 -1.4
 -1.6
 -1.3
CDC6
 CDC6 cell division cycle 6 homolog (S. cerevisiae)
 -1.3
 -1.2
 -1.5
 -1.3
 -1.3
 -1.3
DDIT4
 DNA-damage-inducible transcript 4
 4.4
 3.4
 2.5
 1.2
 4.4
 1.5
FGFR1
 fibroblast growth factor receptor 1
 1.6
 3.1
 1.4
 1.7
 1.7
 1.3
FKBP4
 FK506 binding protein 4, 59 kDa
 -1.9
 -2.1
 -1.3
 -1.5
 -1.6
 *
FKBP5
 FK506 binding protein 5
 6.6
 11.2
 4.4
 3.8
 2.9
 2.8
HDAC1
 histone deacetylase 1
 -1.4
 -1.2
 -1.2
 -1.3
 -1.2
 -1.3
HRAS
 v-Ha-ras Harvey rat sarcoma viral oncogene homolog
 -1.3
 -1.4
 -1.3
 -1.4
 -1.4
 *
ID1
 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein
 -2.6
 -1.7
 -1.2
 -1.9
 -1.6
 -1.4
IFRD1
 interferon-related developmental regulator 1
 -1.8
 -1.2
 -1.6
 -1.6
 -1.3
 *
IL7R
 interleukin 7 receptor
 8.3
 18.0
 6.3
 1.4
 2.5
 *
ITGA6
 integrin, alpha 6
 5.0
 10.2
 2.4
 6.6
 2.8
 1.6
MAP4
 microtubule-associated protein 4
 -1.3
 -1.8
 -1.7
 -1.3
 -1.3
 *
MT1A
 metallothionein 1A (functional)
 1.3
 1.3
 2.2
 1.4
 1.4
 *
MTHFD1
 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1
 -1.4
 -1.9
 -1.5
 -1.5
 -1.2
 *
MYC
 v-myc myelocytomatosis viral oncogene homolog (avian)
 -3.8
 -4.6
 -3.6
 -1.4
 -2.2
 *
NFKBIA
 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
 3.0
 3.4
 2.8
 1.9
 1.5
 1.3
NME1
 non-metastatic cells 1, protein (NM23A) expressed in
 -1.5
 -2.2
 -1.6
 -1.4
 -1.3
 *
NR3C1
 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
 4.2
 6.6
 2.1
 1.7
 1.6
 *
OGT
 O-linked N-acetylglucosamine (GlcNAc) transferase
 1.3
 1.7
 2.0
 1.6
 1.3
 *
PIAS2
 protein inhibitor of activated STAT, 2
 1.2
 1.4
 1.5
 2.0
 1.3
 *
PIK3R1
 phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha)
 2.5
 2.4
 1.7
 2.0
 1.9
 *
RBMS1
 RNA binding motif, single stranded interacting protein 1
 1.4
 2.0
 1.7
 1.6
 1.5
 1.6
SCARB1
 scavenger receptor class B, member 1
 -1.7
 -2.2
 -1.2
 -1.5
 -1.2
 -1.3
SRM
 spermidine synthase
 -1.8
 -3.3
 -1.7
 -1.4
 -1.4
 *
TAGLN2
 transgelin 2
 -1.4
 -2.0
 -1.3
 -1.2
 -1.2
 *
TRAF3IP2
 TRAF3 interacting protein 2
 1.6
 2.1
 1.8
 1.5
 1.4
 1.3
TSC22D3
 TSC22 domain family, member 3
 33.1
 74.0
 20.4
 7.4
 14.3
 5.0
TXNIP
 thioredoxin interacting protein
 2.8
 3.4
 3.7
 1.4
 2.0
 1.2
UBE2S
 ubiquitin-conjugating enzyme E2S
 -1.6
 -1.6
 -1.3
 -1.6
 -1.3
 *
VCL
 vinculin
 1.8
 1.6
 1.9
 1.3
 1.5
 *
YAF2
 YY1 associated factor 2
 1.8
 2.4
 1.6
 1.7
 1.3
 1.6

Regulated transcripts from vehicle or GC-treated samples were evaluated and compared using Spotfire® and Ingenuity® bioinformatics software. Selection criteria for each gene were as follows: probe called present (Methods) on the microarray and regulated ≥ 1.2-fold (net 20% change). GC-mediated transcripts regulated in common in the same direction among sensitive CEM-C7–14 Dex (C7–14 Dx) and CVZ (C7–14 Z), CEM-C1–6 (C1–6 Dx), CEM-C1–15 CVZ (C1–15 Z), and CEM-C1–15 Dex plus FSK (C1–15 Dx+F) cells were obtained. This comparison resulted in 96 regulated genes (see Additional file 1). This list was subsequently compared to Dex-treated resistant CEM-C1–15 cells (C1–15 Dx). Shown is a subset of 35 genes from the original 96 that could be linked via a signaling network (symbol, closed diamond in Additional file 1). Bold type indicates statistically significant regulation p ≤ 0.05 between means of vehicle vs. GC-treated. Symbol, asterisk = gene "absent" by selection criteria.

Miller et al. Cancer Cell International 2007 7:18   doi:10.1186/1475-2867-7-18